PerkinElmer buys Signature Genomic for $90M; Roche pushing for accelerated approval of blockbuster breast cancer therapy;

 @FierceBiotech: Positive MS data may thwart Icahn's plans for Genzyme. Story | Follow @FierceBiotech

 @JohnCFierce: Agios gets $130M upfront in Celgene deal--now that's real money. | Follow @JohnCFierce

> Cancer drugs, emerging markets boost Roche sales. Article

> PerkinElmer has struck a deal to buy Signature Genomic Laboratories for $90 million. For PerkinElmer, the buyout offers a chance to beef up its presence in genetic testing services and molecular diagnostics. Release

> Roche plans to push ahead and file for approval of TDM-1, a closely-watched breast cancer therapy with blockbuster potential. The company hopes to win an expedited approval either later this year or in early 2011. Report

> FDA gets impatient in Apotex warning letter. Article

> VaxGen has struck a deal to acquire diaDexus in an all-stock deal. DiaDexus is private diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. Release

> Shares of Avanir Pharmaceuticals surged on news of its plan to file a response to the FDA soon on its neurological drug Zenvia. Story

And Finally... A cat can recognize a face faster and more efficiently than a supercomputer. That's one reason a feline brain is the model for a biologically-inspired computer project involving the University of Michigan. Release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.